SARC028: A phase II study of anti-PD1 antibody Pembrolizumab (MK-3475) in patients with advanced sarcomas
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Sarcoma Alliance for Research Through Collaboration
Start Date
April 1, 2015
End Date
March 31, 2020
Administered By
Duke Cancer Institute
Awarded By
Sarcoma Alliance for Research Through Collaboration
Start Date
April 1, 2015
End Date
March 31, 2020